The Clinical Efficacy of DFPP in Patients With AAGN

• Status: Terminated
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The clinical efficacy of double filtration plasmapheresis(DFPP) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhi-Hong Liu, M.D.
• Treatments: Cyclophosphamide; Methylprednisolone

Criteria

Inclusion Criteria:

• a diagnosis of ANCA associated vasculitis(AAV), using criteria adapted from the disease definitions of the Chapel Hill consensus conference

• serum positive ANCA and the ANCA level ≥100 relative unit/ml

• with renal involvement and serum creatinine≥3 mg/dl

• written informed consent had been provided.

Exclusion Criteria:

• other secondary vasculitis

• anti-glomerular basement membrane(GBM) positive

• severe infection; hepatitis B antigenemia, anti- hepatitis C virus

• immunodeficiency; or immunoglobulin G(IgG)<2g/l

• life threatening

• renal biopsy show globally sclerotic glomeruli>60% and normal glomeruli<10%

• need renal replacement therapy for more than 4w

• received large dose of methylprednisolone(MP),CTX,mycophenolate mofetil(MMF), plasmapheresis or intravenous immunoglobulin(IVIg) therapy.